Suppr超能文献

SOX9/miR-130a/CTR1 轴调控宫颈癌顺铂耐药。

SOX9/miR-130a/CTR1 axis modulates DDP-resistance of cervical cancer cell.

机构信息

Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China

Xiangya School of Medicine, Central South University, Changsha, Hunan 410011, China

出版信息

Cell Cycle. 2018;17(4):448-458. doi: 10.1080/15384101.2017.1395533. Epub 2018 Feb 8.

Abstract

Cisplatin (DDP) -based chemotherapy is a standard strategy for cervical cancer, while chemoresistance remains a huge challenge. Copper transporter protein 1 (CTR1), a copper influx transporter required for high affinity copper (probably reduced Cu I) transport into the cell, reportedly promotes a significant fraction of DDP internalization in tumor cells. In the present study, we evaluated the function of CTR1 in the cell proliferation of cervical cancer upon DDP treatment. MicroRNAs (miRNAs) have been regarded as essential regulators of cell proliferation, apoptosis, migration, as well as chemoresistance. By using online tools, we screened for candidate miRNAs potentially regulate CTR1, among which miR-130a has been proved to promote cervical cancer cell proliferation through targeting PTEN in our previous study. In the present study, we investigated the role of miR-130a in cervical cancer chemoresistance to DDP, and confirmed the binding of miR-130a to CTR1. SOX9 also reportedly act on cancer chemoresistance. In the present study, we revealed that SOX9 inversely regulated miR-130a through direct targeting the promoter of miR-130a. Consistent with previous studies, SOX9 could affect cervical cancer chemoresistance to DDP. Taken together, we demonstrated a SOX9/miR-130a/CTR1 axis which modulated the chemoresistance of cervical cancer cell to DDP, and provided promising targets for dealing with the chemoresistance of cervical cancer.

摘要

顺铂(DDP)为基础的化疗是宫颈癌的标准策略,而化疗耐药仍然是一个巨大的挑战。铜转运蛋白 1(CTR1),一种铜输入转运体,需要高亲和力的铜(可能是还原的 Cu I)进入细胞,据报道,它促进了肿瘤细胞中 DDP 内化的很大一部分。在本研究中,我们评估了 CTR1 在顺铂处理后宫颈癌细胞增殖中的功能。微小 RNA(miRNA)已被认为是细胞增殖、凋亡、迁移以及化疗耐药的重要调节因子。通过使用在线工具,我们筛选出潜在调节 CTR1 的候选 miRNA,其中 miR-130a 在我们之前的研究中已被证明通过靶向 PTEN 促进宫颈癌细胞增殖。在本研究中,我们研究了 miR-130a 在宫颈癌对 DDP 化疗耐药中的作用,并证实了 miR-130a 与 CTR1 的结合。SOX9 也被报道对癌症化疗耐药有影响。在本研究中,我们揭示了 SOX9 通过直接靶向 miR-130a 的启动子来反向调节 miR-130a。与之前的研究一致,SOX9 可以影响宫颈癌对 DDP 的化疗耐药性。综上所述,我们证实了 SOX9/miR-130a/CTR1 轴调节宫颈癌细胞对 DDP 的化疗耐药性,并为解决宫颈癌化疗耐药性提供了有前途的靶点。

相似文献

1
SOX9/miR-130a/CTR1 axis modulates DDP-resistance of cervical cancer cell.SOX9/miR-130a/CTR1 轴调控宫颈癌顺铂耐药。
Cell Cycle. 2018;17(4):448-458. doi: 10.1080/15384101.2017.1395533. Epub 2018 Feb 8.
4
Modulation of CASC2/miR-21/PTEN pathway sensitizes cervical cancer to cisplatin.CASC2/miR-21/PTEN通路的调控使宫颈癌对顺铂敏感。
Arch Biochem Biophys. 2017 Jun 1;623-624:20-30. doi: 10.1016/j.abb.2017.05.001. Epub 2017 May 8.

引用本文的文献

3
Novel insights into cuproptosis inducers and inhibitors.对铜死亡诱导剂和抑制剂的新见解。
Front Mol Biosci. 2024 Nov 26;11:1477971. doi: 10.3389/fmolb.2024.1477971. eCollection 2024.
10

本文引用的文献

3
Molecular mechanisms of cisplatin resistance in cervical cancer.宫颈癌顺铂耐药的分子机制
Drug Des Devel Ther. 2016 Jun 7;10:1885-95. doi: 10.2147/DDDT.S106412. eCollection 2016.
10
Cisplatin resistance in human cervical, ovarian and lung cancer cells.人宫颈、卵巢和肺癌细胞中的顺铂耐药性。
Cancer Chemother Pharmacol. 2015 Jun;75(6):1217-27. doi: 10.1007/s00280-015-2739-2. Epub 2015 Apr 18.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验